EVUSHELD TREATMENT TIMING SET
People eligible for COVID-19 preexposure prophylaxis (PrEP) with the monoclonal antibody combination of tixagevimab and cilgavimab (Evusheld) should be treated every 6 months to maintain protection against infection, according to the recently revised Fact Sheet for Healthcare Providers.
Full access: JAMA
OVER HALF OF KNOWN HUMAN PATHOGENIC DISEASES CAN BE AGGRAVATED BY CLIMATE CHANGE
Climate change can affect human pathogenic diseases; however, the full extent of this risk remains poorly quantified. Researchers carried out a systematic search for empirical examples about the impacts of ten climatic hazards sensitive to greenhouse gas (GHG) emissions on each known human pathogenic disease. They found that 58% (that is, 218 out of 375) of infectious diseases confronted by humanity worldwide have been at some point aggravated by climatic hazards.
Full Access: Nature
WHEN TO USE ANTIBIOTICS IN COVID-19: A PROPOSAL BASED ON QUESTIONS
Safe antimicrobial stewardship strategies aim to limit indiscriminate use to decrease antimicrobial resistance. The use of antibiotics in COVID-19 is not yet standardized, and there is no evidence for their routine use. There is no evidence to justify the systematic use of antimicrobials in COVID-19. The COVID-19 treatment recommendations seek to provide knowledge regarding treatment; standardizing a management algorithm requires validation in clinical trials and studies of greater methodological rigor.
Full Access: Cureus
ASSESSMENT OF CHANGES IN VISITS AND ANTIBIOTIC PRESCRIBING DURING THE AGENCY FOR HEALTHCARE – Research and Quality Safety Program for Improving Antibiotic Use and the COVID-19 Pandemic
In this cohort study comprising members of 389 US ambulatory practices, the Agency for Healthcare Research and Quality Safety Program for Improving Antibiotic Use Program addressed attitudes and culture that challenge judicious antibiotic prescribing and incorporated best practices for the management of common infections. Between September 2019 and November 2020, antibiotic prescribing at clinic visits decreased from 18% to 9%, and antibiotic prescribing at acute respiratory infection visits decreased from 39% to 25%.
Full Access: JAMA
THE FREQUENCY AND CHARACTERISTICS OF EPINEPHRINE USE DURING IN-FLIGHT ALLERGIC EVENTS
Allergic reactions account for 2-4% of medical events in-flight and 5.5% of all medical events in passengers 18 years and under. A retrospective study of the GBMS showed that epinephrine administration was recommended in 398 passengers. Of those, 328 (82.4%) ultimately received at least one dose of epinephrine. Passengers older than 12 years of age were at a statistically higher risk for epinephrine administration.
Full Access: Annal of Allergy, Asthma & Immunology